Core Viewpoint - Evofem Biosciences is expanding its market presence by commercializing its hormone-free contraceptive PHEXXI in the UAE through a partnership with Pharma 1 Drug Store, targeting a launch in Q1 2026 after regulatory approval [1][2][6]. Group 1: Company Overview - Evofem Biosciences, Inc. focuses on innovative products for women's sexual and reproductive health, generating revenue from FDA-approved products including PHEXXI and SOLOSEC [5][6]. - Pharma 1 Drug Store LLC is an Emirati healthcare company with exclusive commercialization rights for PHEXXI in the Middle East, responsible for regulatory approvals and all commercial functions [2][8]. Group 2: Product Details - PHEXXI is the first FDA-approved locally-acting contraceptive gel, applied before intercourse to maintain a vaginal pH that is inhospitable to sperm and pathogens, without hormones [4]. - The product is expected to meet a growing demand for hormone-free contraception in the UAE and surrounding regions, as indicated by market research [2]. Group 3: Market Strategy - Pharma 1 is developing a commercial strategy for PHEXXI in the UAE, anticipating strong reception among OB/GYNs and women [2]. - The launch quantity order for PHEXXI is planned for July 2025, with the aim to diversify Evofem's revenue stream through sales in the UAE [1][2].
Evofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug Store